Iroko Pharmaceuticals Closes $75M Debt Facility

irokoIroko Pharmaceuticals, LLC, a Philadelphia, PA-based global specialty pharmaceutical company dedicated to advancing the science of analgesia, closed a $75m debt facility agreement with an affiliate of OrbiMed Advisors LLC.

The financing will support general business operations and the launch of ZORVOLEX™ (diclofenac).

Led by Osagie Imasogie, Executive Chairman of the Board, Iroko Pharmaceuticals has developed ZORVOLEX, an FDA approved NSAID, which contains diclofenac as submicron particles that are approximately 20 times smaller than their original size.
ZORVOLEX was approved by the United States Food and Drug Administration (FDA) on October 18, 2013.



Join the discussion